Validation of the oral mucositis assessment scale in pediatric cancer

Pediatric Blood & Cancer
Lillian SungBrian M Feldman

Abstract

Our objective was to examine the construct validity of the Oral Mucositis Assessment Scale (OMAS) in children receiving doxorubicin chemotherapy. Children between 6 and 18 years of age with cancer receiving doxorubicin-containing chemotherapy were included. OMAS was measured on days 7, 10, 14, and 17 after chemotherapy. Other measures of mucositis obtained concurrent with OMAS were the World Health Organization (WHO) mucositis scale and pain visual analogue scale (VAS). We also recorded analgesia administration. Sixteen children were studied for 45 post-chemotherapy cycles and 156 OMAS assessments were performed. OMAS was moderately correlated with WHO scores (r = 0.56; P = 0.0006) whereas correlation with the pain VAS was fair (r = 0.37; P = 0.002). OMAS also had fair correlation with the number of doses of topical analgesia (r = 0.43; P = 0.001) and with the cumulative dose of opioid analgesia (r = 0.38; P = 0.003). The OMAS is valid for use in mucositis clinical trials for children at least 6 years of age.

References

Mar 1, 1989·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·F K SpijkervetD M Mehta
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S T SonisM Horowitz
Mar 19, 2003·European Journal of Cancer Care·Barbara LiebertUNKNOWN National Breast Cancer Centre's Specialist Breast Nurse Project Team

❮ Previous
Next ❯

Citations

Apr 9, 2011·European Archives of Paediatric Dentistry : Official Journal of the European Academy of Paediatric Dentistry·A L RimuloS M Paiva
Aug 29, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Deborah TomlinsonLillian Sung
Aug 6, 2009·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Velia Ramírez-AmadorSergio Ponce-de-León
Oct 27, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Akram F QutobDorothy Keefe
Nov 20, 2012·The Journal of Supportive Oncology·Hannah R WardillRachel J Gibson
Jun 22, 2011·Cancer Treatment Reviews·Rachel J Gibson, Joanne M Bowen
Oct 16, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Deborah TomlinsonLillian Sung
Mar 31, 2016·Journal of Pediatric Gastroenterology and Nutrition·René L ShenPer T Sangild
Apr 17, 2008·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Deborah TomlinsonLillian Sung
Oct 7, 2017·Current Opinion in Supportive and Palliative Care·Joanne M Bowen, Hannah R Wardill
Nov 5, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Deborah TomlinsonLillian Sung
Mar 30, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yih-Lin Chung, Newman N M Pui
Oct 30, 2021·CA: a Cancer Journal for Clinicians·Sharon EladStephen T Sonis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.